We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) closed at $435.76 in the latest trading session, marking a -2.25% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.
Coming into today, shares of the drugmaker had lost 0.56% in the past month. In that same time, the Medical sector gained 5.04%, while the S&P 500 lost 0.03%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is expected to report EPS of $4.79, up 5.97% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.22 billion, up 8.46% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $19.15 per share and a revenue of $13.03 billion, representing changes of +4.08% and +8.57%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.16% higher. Vertex Pharmaceuticals is currently a Zacks Rank #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 23.28. This denotes a premium relative to the industry average Forward P/E of 21.35.
Investors should also note that VRTX has a PEG ratio of 1.69 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.51 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors
Vertex Pharmaceuticals (VRTX - Free Report) closed at $435.76 in the latest trading session, marking a -2.25% move from the prior day. The stock's change was less than the S&P 500's daily loss of 1.62%. Elsewhere, the Dow saw a downswing of 1.87%, while the tech-heavy Nasdaq depreciated by 1.98%.
Coming into today, shares of the drugmaker had lost 0.56% in the past month. In that same time, the Medical sector gained 5.04%, while the S&P 500 lost 0.03%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company is expected to report EPS of $4.79, up 5.97% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $3.22 billion, up 8.46% from the year-ago period.
For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $19.15 per share and a revenue of $13.03 billion, representing changes of +4.08% and +8.57%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.
Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.16% higher. Vertex Pharmaceuticals is currently a Zacks Rank #3 (Hold).
In terms of valuation, Vertex Pharmaceuticals is currently trading at a Forward P/E ratio of 23.28. This denotes a premium relative to the industry average Forward P/E of 21.35.
Investors should also note that VRTX has a PEG ratio of 1.69 right now. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Medical - Biomedical and Genetics industry had an average PEG ratio of 1.51 as trading concluded yesterday.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.